Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments

Левин, О С; Batukaeva, L. A.; Anikina, M A; Yunishchenko, N. A.

doi:10.1007/s11055-010-9377-2

Cited by 9 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Choline alphoscerate produced marked and moderate improvements on cognitive functions more frequently than piracetam (40% and 25%, respectively); while the incidence of deterioration was lower (5% and 15%, p < 0.05). Choline alphoscerate displayed a good profile of tolerability, with mild and short-term side effects only in the 15% of patients investigated [62]. Although limited both in terms of size of the sample investigated and of the length of treatment, the results of this pilot study suggest to further investigate activities of choline alphoscerate also in Parkinson's disease accompanied by cognitive dysfunction.…”

Section: Clinical Efficacymentioning

confidence: 84%

“…An open 10-day study has assessed therapeutic activity of choline alphoscerate in Parkinson's disease with cognitive impairments reaching the level of moderate cognitive disorder or dementia. Forty patients were treated intravenously with 1,000 mg/day compared to piracetam given to 20 patients at a dose of 2,000 mg/day [62]. Choline alphoscerate produced marked and moderate improvements on cognitive functions more frequently than piracetam (40% and 25%, respectively); while the incidence of deterioration was lower (5% and 15%, p < 0.05).…”

Section: Clinical Efficacymentioning

confidence: 99%

See 1 more Smart Citation

Choline Alphoscerate (Alpha-Glyceryl-Phosphoryl-Choline) An Old Choline- containing Phospholipid with a Still Interesting Profile As Cognition Enhancing Agent

Traini¹,

Bramanti²,

Amenta

2013

CAR

View full text Add to dashboard Cite

Cholinergic precursors have represented the first approach to counter cognitive impairment occurring in adultonset dementia disorders. These compounds were early leaved because their clinical efficacy was not clearly demonstrated. This is probably not true for some choline-containing phospholipids including choline alphoscerate. Choline alphoscerate increases the release of acetylcholine in rat hippocampus, facilitates learning and memory in experimental animals, improves brain transduction mechanisms and decreases age-dependent structural changes occurring in rat brain areas involved in learning and memory. The compound exerts neuroprotective effects in models of altered cholinergic neurotransmission and of brain vascular injury. In clinical studies choline alphoscerate improved memory and attention impairment, as well as affective and somatic symptoms in dementia disorders. An ongoing trial indicates that association between the acetylcholinesterase inhibitor donepezil and choline alphoscerate is accompanied by an improvement in several cognitive tests superior to that induced by donepezil alone. It is suggested that this association may represent a therapeutic option to prolong beneficial effects of cholinergic therapies in Alzheimer's disease patients with concomitant ischemic cerebrovascular disorders. In summary, choline alphoscerate has significant effects on cognitive function with a good safety profile and tolerability. Although limited both in terms of size of the samples investigated and of the length of treatment, preclinical and clinical results presented suggest that cognitive enhancing capabilities of choline alphoscerate merit of being further investigated in appropriate trials.

show abstract

Section: Clinical Efficacymentioning

confidence: 84%

Section: Clinical Efficacymentioning

confidence: 99%

Choline Alphoscerate (Alpha-Glyceryl-Phosphoryl-Choline) An Old Choline- containing Phospholipid with a Still Interesting Profile As Cognition Enhancing Agent

Traini¹,

Bramanti²,

Amenta

2013

CAR

View full text Add to dashboard Cite

show abstract

“…Marked and moderate improvement of cognitive functions was found in patients treated with α-GPC compared to the control one. Deterioration of cognitive functions was seen less often in the treated group than in the control group (Levin et al, 2009).…”

Section: Role Of Choline-containing Phospholipids On Neurovascular Un...mentioning

confidence: 74%

Effects of choline containing phospholipids on the neurovascular unit: A review

Roy

Tomassoni

Nittari

et al. 2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

The roles of choline and of choline-containing phospholipids (CCPLs) on the maintenance and progress of neurovascular unit (NVU) integrity are analyzed. NVU is composed of neurons, glial and vascular cells ensuring the correct homeostasis of the blood-brain barrier (BBB) and indirectly the function of the central nervous system. The CCPLs phosphatidylcholine (lecithin), cytidine 5′-diphosphocholine (CDP-choline), choline alphoscerate or α-glyceryl-phosphorylcholine (α-GPC) contribute to the modulation of the physiology of the NVU cells. A loss of CCPLs contributes to the development of neurodegenerative diseases such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease. Our study has characterized the cellular components of the NVU and has reviewed the effect of lecithin, of CDP-choline and α-GPC documented in preclinical studies and in limited clinical trials on these compounds. The interesting results obtained with some CCPLs, in particular with α-GPC, probably would justify reconsideration of the most promising molecules in larger attentively controlled studies. This can also contribute to better define the role of the NVU in the pathophysiology of brain disorders characterized by vascular impairment.

show abstract

“…As a precursor of biological constituents, choline alphoscerate, even for prolonged administration, generally does not pose problems of tolerability. Studies on cognitive impairment, Alzheimer’s, dementia [ 18 ], Parkinson’s [ 19 ], or Cerebral Small Vessel Disease [ 20 ] showed that the incidence of side-effects in the group treated with choline alphoscerate is low and similar to those observed in the placebo group. The possible occurrence of nausea (probably attributable to a secondary dopaminergic activation) could require a reduction in the dosage and/or suspension of the drug.…”

Section: Introductionmentioning

confidence: 99%

Effect of Treatment of the Cholinergic Precursor Choline Alphoscerate in Mild Cognitive Dysfunction: A Randomized Controlled Trial

Carotenuto,

Andreone,

Amenta

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: The focus on mild cognitive dysfunction in adults is of great interest, given the risk of worsening and conversion to dementia. Cognitive dysfunctions are characterized by a decrease in the weight and volume of the brain, due to cortical atrophy, with a widening of the grooves and flattening of the convolutions. Brain atrophy that mainly involves the hippocampus is related to the progression of cognitive impairment and the conversion from mild cognitive dysfunction to dementia. Currently, there is no treatment for MCI. Results from a trial on Alzheimer’s disease (ASCOMALVA trial) suggest that a sustained cholinergic challenge can slow the progression of brain atrophy typical of Alzheimer’s disease associated with vascular damage. This study intends to evaluate the efficacy of choline alphoscerate in patients with mild cognitive impairment (MCI) and associated vascular damage, in stabilizing and/or slowing brain atrophy typical of adult-onset cognitive dysfunction, and in improving and/or slowing the progression of cognitive and behavioral symptoms associated with MCI. Materials and Methods: This randomized controlled trial will recruit 60 patients that will be evaluated and randomized in a 1:1 ratio to receive choline alphoscerate (1200 mg/day) or placebo, for 12 months. Analyses will be carried out using SPSS vesion No 26 the Statistician in charge of this study, with the statistical significance level chosen as 0.05. Discussion: This trial may provide evidence about the efficacy of treatment with the cholinergic precursor choline alphoscerate in patients with mild cognitive dysfunction. The results of this study will be published in peer-reviewed journals. Registration: EudraCT number: 2020-000576-38

show abstract

Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments

Cited by 9 publications

References 15 publications

Choline Alphoscerate (Alpha-Glyceryl-Phosphoryl-Choline) An Old Choline- containing Phospholipid with a Still Interesting Profile As Cognition Enhancing Agent

Choline Alphoscerate (Alpha-Glyceryl-Phosphoryl-Choline) An Old Choline- containing Phospholipid with a Still Interesting Profile As Cognition Enhancing Agent

Effects of choline containing phospholipids on the neurovascular unit: A review

Effect of Treatment of the Cholinergic Precursor Choline Alphoscerate in Mild Cognitive Dysfunction: A Randomized Controlled Trial

Contact Info

Product

Resources

About